Expression of cyclin A and bone morphogenetic protein receptors and response to induction therapy in patients with acute leukemias

• Published in: Leukemia & lymphoma Vol. 52; no. 12; pp. 2336 - 2341
• Main Authors: Dzietczenia, Justyna, Wróbel, Tomasz, Ja wiec, Bo ena, Mazur, Grzegorz, Butrym, Aleksandra, Kuliczkowski, Kazimierz
• Format: Journal Article
• Language: English
• Published: United States Informa Healthcare 01.12.2011; Taylor & Francis
• Subjects: Acute Disease; Acute leukemias; Adolescent; Adult; Aged; Aged, 80 and over; bone morphogenetic protein receptors; Bone Morphogenetic Protein Receptors - metabolism; bone morphogenetic proteins; cell cycle; cyclin A; Cyclin A - metabolism; Female; Humans; Induction Chemotherapy; Leukemia - drug therapy; Leukemia - metabolism; Leukemia - mortality; Male; Middle Aged; Survival Analysis; Treatment Outcome; Young Adult
• ISSN: 1042-8194; 1029-2403
• DOI: 10.3109/10428194.2011.597903

Abstract Bone morphogenetic proteins (BMPs) are multifunctional cytokines that belong to the transforming growth factor β (TGFβ) family. They participate in the regulation of growth, differentiation and apoptosis in a variety of cell types including hematopoietic lineages. To date, the role of BMPs in carcinogenesis has not been well known. Cyclin A is a cell cycle regulatory protein which plays the role of a parameter of cell proliferation in various types of carcinomas including hematological malignancies. The role of BMPRIA, BMPRIB, BMPRI and cyclin A in the pathogenesis of acute leukemias remains unclear. The aim of this study was to evaluate the expression of BMP receptors and cyclin A on blast cells and their possible relationship with clinical outcome. Seventy patients with acute leukemias (28 female and 42 male) and 10 aged-matched healthy controls were studied. All patients were examined before cytostatic treatment. The expression of BMP receptors and cyclin A was detected by flow cytometry. The results show that higher expression of BMPRIA, BMPRIB, BMPRII and cyclin A is related with a higher complete response (CR) rate, higher overall survival (OS) and lower relapse risk. The expressions of BMPRIA, BMPRIB, BMPRII and cyclin A could be useful as prognostic parameters of the proliferation status of acute leukemia cells, but further studies are needed to assess this phenomenon.